Enlivex Therapeutics Ltd (ENLV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 9,736 | 9,005 | 6,871 | 7,286 | 10,583 |
| Marketable Securities | 40 | N/A | 3,007 | 12,046 | 22,028 |
| Receivables | 213 | 95 | 663 | 1,060 | 274 |
| TOTAL | $10,277 | $9,114 | $10,541 | $20,392 | $32,885 |
| Non-Current Assets | |||||
| PPE Net | 685 | 388 | 71 | 91 | 60 |
| Investments And Advances | 0 | 0 | 18 | 33 | 9 |
| Other Non-Current Assets | 72 | 38 | 0 | 0 | 0 |
| TOTAL | $757 | $426 | $89 | $124 | $69 |
| Total Assets | $11,034 | $9,540 | $10,630 | $20,516 | $32,954 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 186 | 62 | 1,931 | 2,514 | 2,280 |
| Accrued Expenses | 944 | 634 | N/A | N/A | N/A |
| TOTAL | $1,130 | $696 | $1,931 | $2,514 | $2,280 |
| Non-Current Liabilities | |||||
| aiOther Non-Current Liabilities | 198 | 351 | 0 | 70 | 0 |
| TOTAL | $198 | $351 | $N/A | $70 | $N/A |
| Total Liabilities | $1,328 | $1,047 | $1,931 | $2,584 | $2,280 |
| Shareholders' Equity | |||||
| Common Shares | 396 | 396 | 45 | 39 | 39 |
| Retained earnings | -16,289 | -12,047 | -39,809 | -23,787 | -8,422 |
| Other shareholders' equity | -2,251 | -1,503 | 0 | 0 | 0 |
| TOTAL | $9,706 | $8,493 | $8,699 | $17,932 | $30,674 |
| Total Liabilities And Equity | $11,034 | $9,540 | $10,630 | $20,516 | $32,954 |